Skip to main content

Table 2 Characteristics of the randomized placebo-controlled trials considered for the guideline in chronic migraine

From: Correction to: European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

Study Study phase Treatment regimen Duration of treatment Participants (n) Women (%) Age range
(years)
Definition of chronic migraine Preventive treatment
(% using)
Exclusion by preventive failure
(n. of drugs/ categories)
Erenumab
 Tepper, 2017 [45] II 70 mg monthly sc
140 mg monthly sc
3 months 667 79–87 18–65 ICHD-3, beta version Not allowed > 3
Fremanezumab
 Bigal, 2015 [26] II 225 mg monthly sc (675 mg ld) 3 months 264 85–86 18–65 ICHD-3, beta version 38–43 > 3
 HALO CM [41] III 225 mg monthly sc (675 mg ld)
675 mg quarterly sc
3 months 1130 87–88 18–70 ICHD-3, beta version 20–22 ≥2
Galcanezumab
 REGAIN [31] III 120 mg monthly sc (240 mg ld)
240 mg monthly sc
3 months 1117 82–87 18–65 ICHD-3, beta version (required at least 1 headache-free day per month) 13–16 > 2
  1. sc: subcutaneous; ld loading dose